Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 35

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 35
---
 our product candidates.

We expect to continue to spend
substantial amounts of our cash resources going forward in order to advance the development of our product candidates. We believe we have
sufficient funds to continue our operations into the first quarter of 2025, and we believe that we will need to raise additional capital
to fund our operations thereafter.

Until such time as we can
generate a sufficient amount of revenue from the product candidates we license, if ever, we expect that we may finance future cash needs
through, among other things, public or private equity or debt offerings. Such offerings may take place in the United Kingdom, the United
States or other foreign countries. However, if we are unable to raise capital when needed, or on terms acceptable to us, our business
could be significantly harmed. If we raise additional funds through the issuance of debt or additional equity securities, such issuance
could result in dilution to our existing shareholders and/or increased fixed payment obligations. Furthermore, these securities may have
rights senior to those of our Ordinary Shares and could contain covenants that would restrict our operations and potentially impair our
competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual
property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events
could significantly harm our business, financial condition and prospects.

Our forecast of the period
of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks
and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this
“Risk Factors” section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize
our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly
faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control.
Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:

| • | any acquisitions and the commercialization of other assets, including licensed assets; |

| • | the initiation, progress, timing, costs and results of clinical trials for any product candidates we advance 
 to clinical trials;                                                                                          |

| • | the attainment of milestones and the need to make any royalty payments on any of our product candidates 
 or any other future product candidates;